Endemic in over Endemic in
100 Countries[3] over 100
Countries[3]
86 Countries
now show evidence
OF ZIKA VIRUS INFECTION[2]
now show
evidence OF
ZIKA VIRUS INFECTION[2]

­estimated $60.3 BILLION

­estimated
$60.3 BILLION
ANNUAL ECONOMIC
IMPACT WORLDWIDE[2]

ANNUAL ECONOMIC
IMPACT WORLDWIDE[2]

Scroll Down

THE NUMBERS ARE CHANGING

THE NUMBERS ARE CHANGING

Take a closer look at worldwide infectious disease facts and statistics. Take a closer look at worldwide infectious
disease facts and statistics.
world map
  • Dengue
    Map shows areas at risk for dengue transmission.
  • Zika
    Map shows areas that have or have had Zika transmission.
  • Norovirus
    Map shows areas with the risk of norovirus transmission.
  • Dengue facts

    About 50% of the world's population lives under the threat of dengue, which is responsible for approximately 390 million infections globally per year.[3]

  • Dengue facts

    Before 1970, only nine countries had experienced severe dengue epidemics. The disease is now endemic in more than 100 countries.[3]

  • Zika facts

    As of July 2018, a total of 86 countries and territories have reported evidence of mosquito-transmitted Zika infection.[4]

  • Zika facts

    As of March 2017, a decline in cases of Zika infection has been reported in some countries, or in some parts of countries; WHO advises that vigilance needs to remain high.[1]

  • Norovirus facts

    Norovirus is the most common viral cause of acute gastroenteritis worldwide, responsible for greater than 90% of epidemic non-bacterial outbreaks of gastroenteritis.[2]

  • Norovirus facts

    Norovirus is estimated to cause more than 699 million illness cases each year.[2]

  • Interested in
    Learning More?

    For updated disease information and statistics, please visit the following websites:

    Back to disease facts and statistics

vaccines change numbers

If all children were

immunized

with existing

vaccines, by 2020

we would

save nearly

25,000,000

lives

If all children were immunized with

existing vaccines,

by 2020 we would

save nearly

25,000,000 lives[7]

Estimated

2-3 MILLION

deaths averted each year with

immunization

from diphtheria, tetanus,

pertussis (whooping cough), and measles

Estimated 2-3 MILLION

deaths averted each year with

immunization

from diphtheria, tetanus, pertussis (whooping cough), and measles [8]

vaccines change lives

infectious diseases
that need our attention

infectious diseases that
need our attention

Learn about some of the diseases we are focusing on. Learn about some of the diseases
we are focusing on.
slide image

DENGUE

About the disease

Dengue fever is the world’s fastest spreading mosquito-borne viral disease with about 50% of the world's population at risk for contracting the disease. Dengue fever affects children and adults alike with flu-like symptoms and potentially deadly complications.[3]

slide image

ZIKA

About the disease:

Zika is a mosquito-borne virus that can be passed from a pregnant woman to her fetus. Though many infected people will not develop any symptoms at all, approximately 10% of congenital infections are associated with Zika virus-associated birth defects. WHO says that 31 countries have currently reported microcephaly and other central nervous system defects potentially associated with Zika virus.[1]

slide image

NOROVIRUS

About the disease:

Norovirus is the most common cause of acute gastroenteritis worldwide. It is highly infectious and easily spreads, mainly through person-to-person contact. All age groups are impacted with the greatest burden on young children, older adults, and other vulnerable populations.[9]

slide image

DENGUE

About the disease

Dengue fever is the world’s fastest spreading mosquito-borne viral disease with about 50% of the world's population at risk for contracting the disease. Dengue fever affects children and adults alike with flu-like symptoms and potentially deadly complications.[3]

slide image

ZIKA

About the disease:

Zika is a mosquito-borne virus that can be passed from a pregnant woman to her fetus. Though many infected people will not develop any symptoms at all, approximately 10% of congenital infections are associated with Zika virus-associated birth defects. WHO says that 31 countries have currently reported microcephaly and other central nervous system defects potentially associated with Zika virus.[1]

slide image

NOROVIRUS

About the disease:

Norovirus is the most common cause of acute gastroenteritis worldwide. It is highly infectious and easily spreads, mainly through person-to-person contact. All age groups are impacted with the greatest burden on young children, older adults, and other vulnerable populations.[9]

WHO WE ARE

WHO WE ARE

OUR VISION

OUR VISION

To protect the health of people everywhere through vaccines that address the most important infectious diseases.

OUR MISSION

OUR MISSION

To develop and deliver innovative vaccines that tackle the toughest problems in public health and improve the lives of people around the world.

OUR VALUES

OUR VALUES

In our day-to-day work, we focus on the following values while upholding the highest ethical standards:

  • .Fairness
  • .Honesty
  • .Integrity
  • .Perseverence

OUR PRODUCTS

OUR PRODUCTS

OUR PRODUCTS MARKETED IN JAPAN
  • .BLB-750 (H5N1 Flu)
  • .Measles Rubella
  • .Mumps
  • .Diphtheria Tetanus Toxoid
  • .Seasonal Flu
    (Denka & Kaketsuken)
  • .Varicella (Biken)
  • .Japanese Encephalitis (Biken)

OUR PRODUCTS MARKETED IN JAPAN

  • .Seasonal Flu
    (Denka & Kaketsuken)
  • .Varicella (Biken)
  • .Japanese Encephalitis
    (Biken)
  • .BLB-750 (H5N1 Flu)
  • .Measles Rubella
  • .Mumps
  • .Diphtheria Tetanus
    Toxoid

OUR VISION

To protect the health of people everywhere through vaccines that address the most important infectious diseases.

OUR MISSION

To develop and deliver innovative vaccines that tackle the toughest problems in public health and improve the lives of people around the world.

OUR VALUES

In our day-to-day work, we focus on the following values while upholding the highest ethical standards:

  • .Fairness
  • .Honesty
  • .Integrity
  • .Perseverence

OUR PRODUCTS

OUR PRODUCTS MARKETED IN JAPAN
  • .BLB-750 (H5N1 Flu)
  • .Measles Rubella
  • .Mumps
  • .Diphtheria Tetanus Toxoid
  • .Seasonal Flu
    (Denka & Kaketsuken)
  • .Varicella (Biken)
  • .Japanese Encephalitis (Biken)

OUR PRODUCTS MARKETED IN JAPAN

  • .Seasonal Flu
    (Denka & Kaketsuken)
  • .Varicella (Biken)
  • .Japanese Encephalitis
    (Biken)
  • .BLB-750 (H5N1 Flu)
  • .Measles Rubella
  • .Mumps
  • .Diphtheria Tetanus
    Toxoid

WE'RE COMMITTED
TO A HEALTHIER FUTURE

WE'RE COMMITTED
TO A HEALTHIER FUTURE

Here's what we are working on: Here's what we are working on:
Pipeline Summary

global pipeline summary

  • Phase 3

     

     

    DENGUE (TAK-003)

  • Phase 2

     

     

    NOROVIRUS (TAK-214)

  • Phase 1

     

     

    ENTEROVIRUS (EV71) (TAK-021)
    ZIKA (TAK-426)

  • Preclinical

     

     

    CHIKUNGUNYA (TAK-507)

slide image

DENGUE

Takeda's vaccine candidate:

A live attenuated tetravalent dengue vaccine is being developed.

Development Phase: Phase 3

slide image

NOROVIRUS

Takeda's vaccine candidate:

A virus-like particle vaccine for two norovirus genotypes is being developed.

Development Phase: Phase 2b

slide image

ENTEROVIRUS 71 (EV71)

Takeda's vaccine candidate:

An inactivated virus vaccine for EV71 is being developed.

Development Phase: Phase 1

slide image

ZIKA

Takeda's vaccine candidate:

An inactivated, adjuvanted, whole Zika virus vaccine is being developed with support from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).

Development Phase: Phase 1

slide image

CHIKUNGUNYA

Takeda's vaccine candidate:

A chikungunya vaccine is being developed in partnership with Zydus Cadila.

Development Phase: Preclinical

slide image

GLOBAL PIPELINE SUMMARY

  • Phase 3
    DENGUE (TAK-003)
  • Phase 2
    NOROVIRUS (TAK-214)
  • Phase 1
    ENTEROVIRUS 71 (EV71) (TAK-021)
    ZIKA (TAK-426)
  • Preclinical
    CHIKUNGUNYA (TAK-507)
slide image

DENGUE

Takeda's vaccine candidate:

A live attenuated tetravalent dengue vaccine is being developed.

Development Phase: Phase 3

slide image

NOROVIRUS

Takeda's vaccine candidate:

A virus-like particle vaccine for two norovirus genotypes is being developed.

Development Phase: Phase 2b

slide image

ENTEROVIRUS 71 (EV71)

Takeda's vaccine candidate:

An inactivated virus vaccine for EV71 is being developed.

Development Phase: Phase 1

slide image

ZIKA

Takeda's vaccine candidate:

An inactivated, adjuvanted, whole Zika virus vaccine is being developed with support from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).

Development Phase: Phase 1

slide image

CHIKUNGUNYA

Takeda's vaccine candidate:

A chikungunya vaccine is being developed in partnership with Zydus Cadila.

Development Phase: Preclinical

leading the way

leading the way

Meet the people who are committed to making change. Meet the people who are committed
to making change.
Takeda Vaccine Business Leadership
Takeda Vaccine Business Leadership
Our team is working passionately toward improving public health.
Click to meet our leaders Swipe to meet our leaders
slide image

RAJEEV VENKAYYA, MD

President, Takeda Vaccine Business

Rajeev is President of the Takeda Vaccine Business. He joined Takeda in 2012 to launch the global vaccine business. He was previously Director of Vaccine Delivery in the Global Health Program at the Bill & Melinda Gates Foundation, and prior to that, Special Assistant to the President for Biodefense at the White House.

slide image

JOHN BOSLEGO, MD

Head of Development

John is Head of Development for the Takeda Vaccine Business. His prior experience includes Director of the Vaccine Development Global Program at PATH, Executive Director at Merck Research Laboratories and the Deputy Director at the Walter Reed Army Institute of Research in Washington, DC.

slide image

Gary Dubin, MD

Head of Global Medical Office

Gary is Head of the Global Medical Office, and leads the Takeda Vaccine Business Medical Affairs and Policy team. He is responsible for vaccines safety and medical governance. Before joining Takeda, Gary spent the previous 20 years at GSK Vaccines.

slide image

Hansi Dean, PhD

Head of Discovery Research

Hansi is Head of Discovery Research for the Takeda Vaccine Business. Hansi joined Takeda in 2014. She was previously Director of New Alliances at the International AIDS Vaccine Initiative, and prior to that a Director at PowderJect and Group Leader for Viral Vaccine Development at Schering Plough.

slide image

Tetsu Inada, BS, MBA

Head of Finance

Tetsu has been Head of Finance for the Takeda Vaccine Business since 2013. Prior to that Tetsu was at Millennium Pharmaceuticals since 2001, and he joined Takeda through the acquisition of Millennium in 2008.

slide image

TAKAYUKI NAKANO, PhD, MBA

Head of Business Planning, Japan Business Coordinator

Takayuki is Head of Business Planning and Japan Business Coordinator. As Head of Business Planning, Takayuki is responsible for business strategy planning, vaccine portfolio management and ensuring organizational governance. As Japan Business Coordinator, he works on strengthening coordination between Japan-based functions and their global counterparts. Takayuki joined Takeda in 2000 and worked in Takeda’s R&D organization prior to joining the Vaccine business.

slide image

Paula Blalock

Head of Vaccine Quality

Paula is the Head of Quality for the Takeda Vaccine Business. She has 35 years of pharmaceutical experience in various functional roles, including manufacturing, quality control microbiology and local/global quality assurance roles at Pfizer, Wyeth and Alcon. Her experience includes international on-site assignments and responsibility for global sites and service providers.

slide image

Claudia Kelly, MBA, MPH

Interim Head of Global Commercial and Head of Global Market Access

Claudia is the Interim Head of Global Commercial and Head of Global Market Access for the Takeda Vaccine Business. Claudia has more than 20 years of experience in corporate and global roles including product strategy, franchise management, pricing strategy, market access, medical affairs, and commercial operations. Prior to joining Takeda in 2017, she worked on numerous vaccine launches for Merck & Co, the Novartis Vaccine Division and Seqirus.

slide image

Amy Atwood

Head of Vaccine Communications

Amy is Head of Communications for the Takeda Vaccine Business, prior to which she was Director of Public Relations for Takeda’s Global Oncology Business Unit. Amy has more than 20 years of experience in all facets of corporate communications, including communication leadership roles at Genzyme, Sanofi Oncology and National Grid.

Our team is working passionately toward improving public health.

slide image

RAJEEV VENKAYYA, MD

President, Takeda Vaccine Business

Rajeev is President of the Takeda Vaccine Business. He joined Takeda in 2012 to launch the global vaccine business. He was previously Director of Vaccine Delivery in the Global Health Program at the Bill & Melinda Gates Foundation, and prior to that, Special Assistant to the President for Biodefense at the White House.

slide image

JOHN BOSLEGO, MD

Head of Development

John is Head of Development for the Takeda Vaccine Business. His prior experience includes Director of the Vaccine Development Global Program at PATH, Executive Director at Merck Research Laboratories and the Deputy Director at the Walter Reed Army Institute of Research in Washington, DC.

slide image

Gary Dubin, MD

Head of Global Medical Office

Gary is Head of the Global Medical Office, and leads the Takeda Vaccine Business Medical Affairs and Policy team. He is responsible for vaccines safety and medical governance. Before joining Takeda, Gary spent the previous 20 years at GSK Vaccines.

slide image

Hansi Dean, PhD

Head of Discovery Research

Hansi is Head of Discovery Research for the Takeda Vaccine Business. Hansi joined Takeda in 2014. She was previously Director of New Alliances at the International AIDS Vaccine Initiative, and prior to that a Director at PowderJect and Group Leader for Viral Vaccine Development at Schering Plough.

slide image

Tetsu Inada, BS, MBA

Head of Finance

Tetsu has been Head of Finance for the Takeda Vaccine Business since 2013. Prior to that Tetsu was at Millennium Pharmaceuticals since 2001, and he joined Takeda through the acquisition of Millennium in 2008.

slide image

TAKAYUKI NAKANO, PhD, MBA

Head of Business Planning, Japan Business Coordinator

Takayuki is Head of Business Planning and Japan Business Coordinator. As Head of Business Planning, Takayuki is responsible for business strategy planning, vaccine portfolio management and ensuring organizational governance. As Japan Business Coordinator, he works on strengthening coordination between Japan-based functions and their global counterparts. Takayuki joined Takeda in 2000 and worked in Takeda’s R&D organization prior to joining the Vaccine business.

slide image

Paula Blalock

Head of Vaccine Quality

Paula is the Head of Quality for the Takeda Vaccine Business. She has 35 years of pharmaceutical experience in various functional roles, including manufacturing, quality control microbiology and local/global quality assurance roles at Pfizer, Wyeth and Alcon. Her experience includes international on-site assignments and responsibility for global sites and service providers.

slide image

Claudia Kelly, MBA, MPH

Interim Head of Global Commercial and Head of Global Market Access

Claudia is the Interim Head of Global Commercial and Head of Global Market Access for the Takeda Vaccine Business. Claudia has more than 20 years of experience in corporate and global roles including product strategy, franchise management, pricing strategy, market access, medical affairs, and commercial operations. Prior to joining Takeda in 2017, she worked on numerous vaccine launches for Merck & Co, the Novartis Vaccine Division and Seqirus.

slide image

Amy Atwood

Head of Vaccine Communications

Amy is Head of Communications for the Takeda Vaccine Business, prior to which she was Director of Public Relations for Takeda’s Global Oncology Business Unit. Amy has more than 20 years of experience in all facets of corporate communications, including communication leadership roles at Genzyme, Sanofi Oncology and National Grid.

1World

It's the single thing that
that connects us all